Table 1.
Baseline cohort characteristics
| Cardiotoxicity of Cancer Therapy Subcohort | Female Healthy Control Participants | |
|---|---|---|
| N = 142 | N = 21 | |
| Age (years) | 49 (41, 56)* | 36 (27, 51) |
| Race | ||
| Caucasian | 93 (65) | 9 (43) |
| Black | 35 (25) | 7 (33) |
| Other or unknown | 14 (10) | 5 (23) |
| Body Mass Index (kg/m2) | 26 (24, 30) | 24 (22, 27) |
| Systolic blood pressure (mmHg) | 125 (116, 134) | 116 (110, 127) |
| Diastolic blood pressure (mmHg) | 74 (68, 81) | 76 (68, 80) |
| Heart rate (beats per minute) | 77 (72, 87) | 71 (63, 77) |
| Chemotherapy regimen | ||
| Doxorubicin | 129 (91) | |
| Doxorubicin + Trastuzumab | 13 (9) | |
| Radiation therapy | 84 (59) | |
| History of diabetes | 11 (8) | |
| History of hypertension | 33 (23) | |
| History of hyperlipidemia | 30 (21) | |
| Smoking status | ||
| Never | 82 (58) | 18 (86) |
| Former | 48 (34) | 3 (15) |
| Current | 12 (8) | 1 (5) |
| Use of any cardiac medication | 21 (15) | |
| ACE inhibitor | 11 (8) | |
| Angiotensin receptor blocker | 5 (4) | |
| Beta blocker | 9 (6) | |
| 3D LVEF (%)† | 49.9 (43.6, 54.6) † | 57.0 (54.3, 62.0)* |
| GCS (%)† | −22.0 (−25.7, −18.5) † | −27.2 (−30.9, −24.7)* |
| GLS (%)† | −14.6 (−17.0, −12.3) † | −18.7 (−20.7, −17.5)* |
| Principal strain (%)† | −25.4 (−29.0, −21.7) † | −30.1 (−32.4, −27.2)* |
| Twist (°)† | 9.0 (6.3, 12.5) † | 10.3 (7.4, 13.9) |
| Torsion (°/cm) † | 1.1 (0.8, 1.6) † | 1.3 (1.0, 1.8) |
Variables displayed as median (IQR) or N (%)
†
Echocardiographic values are post-anthracycline for the cancer subcohort
*
P<0.001 comparison of post-anthracycline time point and healthy control via Wilcoxon rank sum test.
3D indicates three-dimensional; LVEF, left ventricular ejection fraction; GCS, global circumferential strain; and GLS, global longitudinal strain.